Simvastatin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Mixed into mouse food at two doses from 9 months of age, simvastatin did not change how long mice lived, in males or females. In 20,536 high-risk adults, it cut deaths from any cause from 14.7 percent to 12.9 percent over five years. Both results are real. They answer different questions.
Evidence grade for Simvastatin: Strong. The rule: at least two finished studies in people, and at least 1,000 people who took it. The sum on this page: 2 completed trials, 24,980 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 24,980
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
Approved and widely used for high blood fats such as cholesterol, and to lower the risk of heart and blood vessel disease. No approval and no use related to ageing or lifespan.
6 effects reported, 4 unwanted, 2 wanted, by people using it, not a trial
Goal pages: Ageing and longevity, Heart and circulation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Simvastatin is a cheap, common cholesterol pill, sold as Zocor. It lowers LDL, the so-called bad cholesterol. It is a prescription drug. It is not approved for anything to do with ageing.
What people take it for
- Lower cholesterol.
- Fewer heart attacks and strokes.
- Some hope it slows ageing itself.
What studies in people showed
The human studies are huge. In 20,536 UK adults at high heart risk, deaths from any cause fell from 14.7 percent to 12.9 percent over five years. In 4,444 people with heart disease, 8 percent died on the drug, against 12 percent on a dummy pill. Heart attacks and strokes fell by about a quarter. Now the mice. A US program fed it to mice at two doses. They did not live any longer. Mice do not get clogged heart arteries, so this tests a different question. No study has tested it in healthy people for long life.
What people report
Reports, not study results
The good
- On forums, one side keeps pointing to the big studies showing fewer heart attacks and strokes, and stays on it for that reason.
- In the big studies, extra muscle damage was rare, about 0.01 percent a year.
The bad
- Muscle aches, cramps and leg pain are the main complaints. Some people stop after months, some after a couple of years.
- At least one person says the muscle symptoms lasted long after stopping.
- Higher blood sugar and a worse HbA1c are given as reasons to stop.
- Some raise erection problems, usually as a question rather than a report.
Where these come from: Statin threads on ExcelMale, read in September 2026, plus the studies on this page. Forum reports are not from a study.
My bottom line
If your blood work and history put you at real heart risk, the evidence for this drug is as strong as it gets. It is not a live-longer pill for healthy people. Get a lipid panel and talk to your doctor.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Simvastatin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Living longer24,980 people · 2 studies
- Cholesterol and blood fats20,536 people · 1 study
- Heart attacks and strokes4,444 people · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Simvastatin, what they expect, and what goes wrong. The full account, including the negative reports, is below.
31 of the 36 indexed goals have no study of any kind behind Simvastatin
No study in people, animals or cells on this page reports a result for these. That does not prove Simvastatin does nothing for them. It does mean anything you have heard about Simvastatin and one of these did not come from a study cited here.
Show full evidence
What is Simvastatin?
Mixed into mouse food at two doses from 9 months of age, simvastatin did not change how long mice lived, in males or females. In 20,536 high-risk adults, it cut deaths from any cause from 14.7 percent to 12.9 percent over five years. Both results are real. They answer different questions.
Simvastatin makes the point of this page all by itself.
The Interventions Testing Program fed it to mice at two doses, starting at 9 months of age. The same test run found one of the program's biggest wins. Rapamycin made mice live longer, on average 10 percent longer for males and 18 percent for females, at each of three labs. Resveratrol did nothing. Simvastatin did nothing, at either dose, in either sex.
The human record is huge. In the Scandinavian Simvastatin Survival Study, 4,444 people with chest pain or a past heart attack took simvastatin or a dummy pill. They were followed for about 5.4 years. 12 percent of the dummy group died, against 8 percent on simvastatin. In the Heart Protection Study, 20,536 UK adults at high risk of heart disease took 40 mg a day or a dummy pill. Deaths from any cause fell from 14.7 percent to 12.9 percent. Heart attacks, strokes and similar events fell by about a quarter.
These results do not clash. Lab mice in a clean cage do not die of clogged heart arteries. A drug that prevents heart attacks has nothing to prevent in a mouse that was never going to have one. The mouse result speaks to one claim, that statins slow ageing itself. It says nothing about the heart claim, which is settled.
How does Simvastatin work?
It blocks an enzyme the liver uses to make cholesterol. With less cholesterol being made, the liver pulls more LDL, the so-called bad cholesterol, out of the blood. The same chemical pathway also makes other building blocks that cells use for signalling. Blocking those is thought to cause some side benefits, like less swelling in blood vessels. It is also the most likely cause of the muscle aches some people get on statins. The idea that statins slow ageing rested on those side benefits, not on the cholesterol drop. That is because lab mice do not get the clogged arteries statins prevent in people.
What have studies in people found about Simvastatin?
One of the best-tested drugs in medicine for heart attacks and strokes. Two big studies with a dummy-pill group, nearly 25,000 people in total, both counted deaths. No study has looked at lifespan in people without heart risk, or at any ageing measure.
- Heart Protection Study, 20,536 high-risk adults: deaths from any cause were 12.9 percent on the drug, against 14.7 percent on the dummy pill. Heart attacks, strokes and similar events fell about a quarter over five years.
- In that study the benefit showed up across groups, including women, people over 70, and people who started with low LDL cholesterol.
- Scandinavian study, 4,444 people with heart disease: 8 percent died on simvastatin, against 12 percent on the dummy pill, over about 5.4 years.
- Extra muscle damage in the Heart Protection Study was about 0.01 percent a year. There was no extra cancer, and no extra hospital stays for other reasons.
- No study has tested simvastatin in healthy people to see if they live longer or stay healthier.
What this does not tell you: Everything proven here is about heart attacks and strokes in people who already have heart risk. That is a different group, a different result and a different claim from slowing ageing. The mouse study is the closest anyone has come to testing whether statins slow ageing. It found nothing, at both doses, in both sexes.
What do people who took Simvastatin report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Almost never discussed on its own. Threads treat statins as a class and move between this one and atorvastatin inside the same conversation, so very little of what is said isolates this drug from the others.
- Muscle symptoms dominate the negative reports: aching, cramping and leg pain, sometimes alongside raised liver enzymes. People describe stopping after months or after a couple of years, and at least one account describes symptoms persisting long after stopping rather than clearing quickly.
- Raised blood sugar and a worsened HbA1c are given as reasons for stopping. Erectile function is raised as a concern too, though less consistently and usually as a question rather than a report.
- What people describe moving to instead is niacin at gram amounts, red yeast rice, omega-3, vitamin D and dietary change, with some reporting better panels afterwards without the drug.
- The threads split sharply and stay split. One side posts trial evidence that it lowers the risk of heart attack and stroke, the other posts personal accounts of harm and questions the industry behind the data. Neither side moves, and that split describes the discussion better than any conclusion drawn inside it.
Sources: Statin threads on ExcelMale, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
The state of the research
When this program finds no lifespan effect, that is a real, costly, careful result. It is also narrower than it sounds. It tested one amount in the food, started at one age, in one kind of mouse, and it counted deaths. A no-effect result tells you that this dose, in these mice, did not change how long they lived. It does not tell you the compound does nothing. It does not tell you a different dose would fail, that the idea behind it is wrong, or that the reason people actually take it has been disproved. Those are separate questions, and most were never asked. This site tries to avoid mistakes in both directions. A mouse lifespan win is not proof a supplement works. A mouse lifespan miss is not proof it does nothing.
Simvastatin is the best example of that point. Someone reading only the mouse result would think statins do nothing. Someone reading only the human studies would think statins are a live-longer drug. Both are wrong. The two sets of studies measured different things, in groups that die of different causes.
Well-kept lab mice do not die of clogged heart arteries. So a drug whose whole proven benefit is preventing that disease has nothing to prevent in them. The mouse result was arguably predictable. It is still worth having, because the idea being tested was not about cholesterol. It was that statins calm swelling in the body in a way that slows ageing in general. At the doses used, that idea failed.
The Interventions Testing Program is paid for by the US National Institute on Aging. It runs each test at three separate labs at the same time, in Bar Harbor, Ann Arbor and San Antonio. It uses a mixed breed of mice, a cross of four strains, so no result can come from one odd strain. It tests males and females. Each group is big enough to spot about a 10 percent change in lifespan. Each compound is mixed into the food from a set age. And the program promises in advance to publish results that show nothing, alongside the ones that work. That promise is why this page can exist. Almost nothing else in ageing research reliably tells you what did not work.
The evidence, in charts
Fig. 1a · how many people
24,980people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| Lancet 2002 | 20,536 | 82% |
| Lancet 1994 | 4,444 | 18% |
One study holds 82% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Animal study · done in animals133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 1994 to 2011, counted from the list of sources on this page. The newest source on file is from 2011, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 418.6 Da. A small molecule, not a peptide.
- Half-life
- About 2 hoursShort, 1 to 6 hours
- Chain length
- None on file
Half-life as stated on file: About 2 hours for the parent drug, though the effect on cholesterol synthesis outlasts plasma exposure, which is why it is dosed once daily.
No amino acid sequence is on file for Simvastatin, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people1994Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Lowering cholesterol with a statin kept people alive, and this is the trial that showed it. 4,444 people who already had chest pain or a previous heart attack were split by chance into two groups. One took simvastatin, the other a dummy pill, and both were followed for over five years. By the end, 12 percent of the dummy group had died against 8 percent on the drug. Deaths from heart disease fell from 189 to 111. Everyone here already had heart disease, so this says nothing about healthy people.
4,444 people with angina or previous myocardial infarction, randomised double-blind, median follow-up 5.4 years. 256 placebo patients (12 percent) died against 182 on simvastatin (8 percent), relative risk of death 0.70 (95 percent CI 0.58 to 0.85, p equals 0.0003). Coronary deaths fell from 189 to 111. Major coronary events occurred in 28 percent on placebo and 19 percent on simvastatin.
- Study in people2002MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial
The benefit held even in people whose cholesterol already looked normal. 20,536 UK adults aged 40 to 80 with clogged arteries or diabetes were split by chance. One group took 40 mg of simvastatin a day, the other took a dummy pill. 14.7 percent of the dummy group died of any cause, against 12.9 percent on the drug. Heart attacks, strokes and similar events fell from about a quarter of people to a fifth. Muscle damage did happen, in roughly one person in ten thousand each year.
20,536 UK adults aged 40 to 80 with coronary, other occlusive arterial disease or diabetes, randomised to 40 mg simvastatin daily or placebo. All-cause mortality 12.9 percent versus 14.7 percent (p equals 0.0003). Major vascular events fell 24 percent, from 25.2 percent to 19.8 percent. Benefit held even in participants entering with LDL cholesterol below 3.0 mmol/L. The annual excess risk of myopathy was about 0.01 percent.
- Animal study2011Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice
In mice. Simvastatin mixed into food at two doses did not change how long male or female mice lived. Resveratrol did nothing either. In the same test, rapamycin started at 9 months made mice live longer, on average 10 percent for males and 18 percent for females, at each of three labs.
Interventions Testing Program. Simvastatin at 12 and 120 ppm in the diet had no significant effect on survival in male or female mice. Resveratrol at 300 and 1200 ppm also had none. In the same cohort rapamycin, started at 9 months, extended median survival by an average of 10 percent in males and 18 percent in females, including maximum life span, at each of three test sites.
Common questions
Has Simvastatin been tested in people?
Yes. 24,980 people given it across 2 completed trials cited here, 0 of which found nothing. Mixed into mouse food at two doses from 9 months of age, simvastatin did not change how long mice lived, in males or females. In 20,536 high-risk adults, it cut deaths from any cause from 14.7 percent to 12.9 percent over five years. Both results are real. They answer different questions.
What is the Simvastatin dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. Approved and widely used for high blood fats such as cholesterol, and to lower the risk of heart and blood vessel disease. No approval and no use related to ageing or lifespan.
Is Simvastatin FDA-approved?
Approved and widely used for high blood fats such as cholesterol, and to lower the risk of heart and blood vessel disease. No approval and no use related to ageing or lifespan.
Do statins extend lifespan?
In mice, simvastatin did not, at either of two doses, in the National Institute on Aging's testing program. In people at high risk of heart disease, it cuts deaths from any cause. In a study of 20,536 people, deaths fell from 14.7 percent to 12.9 percent over five years. That means fewer deaths from heart and blood vessel disease. It does not show that ageing slowed down.
Does the mouse null mean statins do not work?
No, and this is the most important thing on the page. The mouse study asked whether simvastatin slows ageing in an animal that does not get clogged arteries. The human studies asked whether it prevents heart attacks and strokes in people who do. The first answer is no. The second is yes, in two of the largest careful studies ever run.
Should a healthy person take a statin for longevity?
No study answers that. Every survival benefit shown for simvastatin comes from people who already had heart disease, other blocked arteries, or diabetes. The one direct test of the ageing idea, in mice, found nothing.
What about muscle side effects?
In the Heart Protection Study, the extra yearly risk of muscle damage on 40 mg a day was about 0.01 percent. That is small but not zero. Muscle aches are the most common reason people stop. That is a talk to have with the doctor who prescribes it. This page cannot settle it.